Medicare Coverage Decision for Pacific Edge Under Review

Pacific Edge (NZX: PEB) is awaiting a decision from Novitas and the Centers for Medicare & Medicaid Services (CMS) on the Local Coverage Determination (LCD) for 'Genetic Testing for Oncology' (DL 39365). The finalization was expected within 365 days of posting, but no timeline is available.

Meanwhile, Pacific Edge’s Cxbladder tests continue to receive Medicare and Medicare Advantage reimbursements as per historical rates, adhering to medical necessity guidelines. The company remains optimistic about the LCD's finalization but will update shareholders once more information is available. No further comments will be made until then.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com